Download pdf
Advances in drug screening and toxicity testing: A review on Parkinson's disease using brain-on-a-chip
- 1 Georgia Institute of Technology
* Author to whom correspondence should be addressed.
Abstract
Neurodegenerative diseases like Parkinson's disease (PD) pose substantial challenges to health and well-being. PD is characterized by the progressive degeneration of dopamine-producing neurons in the substantia nigra of the brain, leading to motor dysfunction, cognitive decline, and various non-motor symptoms. Advances in drug screening and toxicity testing have transformed the study of neurodegenerative diseases. Traditional methods often fall short in replicating the intricate environment of the human brain, highlighting the necessity for alternative pre-clinical models. Brain-on-a-chip technology, an innovative in vitro platform, offers a promising solution by simulating the intricate architecture and microenvironment of brain tissue. This microfluidic device incorporates living brain cells within a controlled setting, enabling the examination of neuronal behavior, disorder mechanisms, and pharmacological responses in a physiologically relevant context. This review examines recent advancements in brain-on-a-chip systems for PD research, emphasizes their potential to advance drug discovery and toxicity testing, also discusses the difficulty and limitations of current brain-on-a-chip technologies, for examples, challenges of specific neuron cell selection and incubation, and also restriction of organ-organ connection. By comparing in vitro and in vivo studies, brain-on-a-chip technology shows great promise for accelerating the development of effective therapies for PD, ultimately contributing to improved patient outcomes and a deeper understanding of the disease.
Keywords
Brain-on-a-Chip, Parkinson's disease, Drug Toxicity.
[1]. Manrique de Lara A., Soto-Gómez L., Núñez-Acosta E., Saruwatari-Zavala G., Rentería M.E. Ethical issues in susceptibility genetic testing for late-onset neurodegenerative diseases. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 180(8):609–21 (2019).
[2]. Cupidi C., Realmuto S., Coco G.L., Cinturino A., Talamanca S., Arnao V., et al. Sleep quality in caregivers of patients with Alzheimer’s disease and Parkinson’s disease and its relationship to quality of life. International Psychogeriatrics. Nov;24(11):1827–35 (2012).
[3]. Lo Bianco C., Ridet J.L., Schneider B.L., Déglon N., Aebischer P. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson’s disease. Proceedings of the National Academy of Sciences. Aug 6;99(16):10813–8 (2002).
[4]. Surmeier D.J. Determinants of dopaminergic neuron loss in Parkinson’s disease. FEBS J. Oct;285(19):3657–68 (2018).
[5]. Fang C., Lv L., Mao S., Dong H., Liu B. Cognition Deficits in Parkinson’s Disease: Mechanisms and Treatment. Parkinsons Dis. Mar 24;2020:2076942 (2020).
[6]. Aarsland D., Batzu L., Halliday G.M., Geurtsen G.J., Ballard C., Ray Chaudhuri K., et al. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers. Jul 1;7(1):1–21 (2021).
[7]. Wakabayashi, K., Tanji, K., Odagiri, S. et al. The Lewy Body in Parkinson’s Disease and Related Neurodegenerative Disorders. Mol Neurobiol 47, 495–508 (2013).
[8]. Jankovic J., Tan E.K. Parkinson’s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. Aug 1;91(8):795–808 (2020).
[9]. Ntetsika T., Papathoma P.E., Markaki I. Novel targeted therapies for Parkinson’s disease. Molecular Medicine. Feb 25;27(1):17 (2021).
[10]. Lee TK, Yankee EL. A review on Parkinson's disease treatment. Neuroimmunology and Neuroinflammation. 8: 222 (2021).
[11]. Pires, A. O., Teixeira, F. G., Mendes-Pinheiro, B., Serra, S. C., Sousa, N., & Salgado, A. J. Old and new challenges in Parkinson’s disease therapeutics. Progress in Neurobiology, 156, 69–89 (2017). doi:10.1016/j.pneurobio.2017.04.006
[12]. Gasser, T. Identifying PD-causing genes and genetic susceptibility factors. Recent Advances in Parkinson’s Disease: Basic Research, pp.2–20 (2010).
[13]. Koszła, O.; St ˛epnicki, P.; Zi ˛eba, A.; Grudzi ´nska, A.; Matosiuk, D.; Kaczor, A.A. Current Approaches and Tools Used in Drug Development against Parkinson’s Disease. Biomolecules,11, 897 (2021).
[14]. Singleton, A. B., Farrer, M. J., & Bonifati, V. The genetics of Parkinson’s disease: Progress and therapeutic implications. Movement Disorders, 28(1), 14–23 (2013).
[15]. Di Monte, D. A., Lavasani, M., & Manning-Bog, A. B. Environmental Factors in Parkinson’s Disease. NeuroToxicology, 23(4-5), 487–502 (2002).
[16]. Drechsel, D. A., & Patel, M. Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson’s disease. Free Radical Biology and Medicine, 44(11), 1873–1886 (2008).
[17]. Linchi Rani, Manas Ranjan Sahu, Amal Chandra Mondal. Age-related Mitochondrial Dysfunction in Parkinson's Disease: New Insights Into the Disease Pathology, Neuroscience, Volume 499, pp.152-169 (2022).
[18]. Koszła, O., Stępnicki, P., Zięba, A., Grudzińska, A., Matosiuk, D., & Kaczor, A. A. Current Approaches and Tools Used in Drug Development against Parkinson’s Disease. Biomolecules, 11(6), 897 (2021).
[19]. Fernanda Martins Lopes, Rafael Schröder, et al. Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies, Brain Research, Volume 1337, pp.85-94 (2010).
[20]. Bhatia, S. N., & Ingber, D. E. Microfluidic organs-on-chips. Nature Biotechnology, 32(8), 760–772 (2014). Pediaditakis, I., Kodella, K.R., Manatakis, D.V. et al. Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption. Nat Commun 12, 5907 (2021).
[21]. Bang, S., Lee, S., Choi, N., & Kim, H. N. Emerging Brain‐Pathophysiology‐Mimetic Platforms for Studying Neurodegenerative Diseases: Brain Organoids and Brains‐on‐a‐Chip. Advanced Healthcare Materials, 2002119 (2021). doi:10.1002/adhm.202002119.
[22]. Kane, K. I. W., Moreno, E. L., et al. Automated microfluidic cell culture of stem cell derived dopaminergic neurons. Scientific Reports, 9(1) (2019).
[23]. Moreno, E. L., Hachi, S., Hemmer, K., et al. Differentiation of neuroepithelial stem cells into functional dopaminergic neurons in 3D microfluidic cell culture. Lab on a Chip, 15(11), 2419–2428 (2015).
[24]. Rappold, P. M., & Tieu, K. Astrocytes and therapeutics for Parkinson’s disease. Neurotherapeutics, 7(4), 413–423 (2010). . doi:10.1016/j.nurt.2010.07.001
[25]. Osaki T., Shin Y., Sivathanu V., Campisi M., Kamm R.D. In Vitro Microfluidic Models for Neurodegenerative Disorders, pp. 7 (2018).
[26]. Fernandes, J. T. S., Chutna, O., Chu, V., Conde, J. P., & Outeiro, T. F. A Novel Microfluidic Cell Co-culture Platform for the Study of the Molecular Mechanisms of Parkinson’s Disease and Other Synucleinopathies. Frontiers in Neuroscience, pp.10 (2016).
[27]. Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications. Cells, 9(7), 1687 (2020).
[28]. White, A. J., Wijeyekoon, R. S., Scott, K. M., et al. The Peripheral Inflammatory Response to Alpha-Synuclein and Endotoxin in Parkinson’s Disease. Frontiers in Neurology, pp.9 (2018).
[29]. Pediaditakis, I., Kodella, K.R., Manatakis, D.V. et al. Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption. Nat Commun 12, 5907 (2021) .
[30]. Miccoli, B., Braeken, D., & Li, Y.C. E. Brain-on-a-chip devices for drug screening and disease modeling applications. Current Pharmaceutical Design, pp.25 (2019).
[31]. Aldewachi, H., Al-Zidan, R. N., Conner, M. T., & Salman, M. M. High-Throughput Screening Platforms in the Discovery of Novel Drugs for Neurodegenerative Diseases. Bioengineering, 8(2), 30 (2021).
[32]. Pamies, D., Hartung, T., & Hogberg, H. T. Biological and medical applications of a brain-on-a-chip. Experimental Biology and Medicine, 239(9), 1096–1107 (2014).
[33]. Schmerbeck, S., Schulze, F., Scheinpflug, J., & Ebrahimi, L. Organ-on-chip systems and the 3Rs. Science in School, 54(2021).
[34]. Bang, S., Jeong, S., Choi, N., & Kim, H. N. Brain-on-a-chip: A history of development and future perspective. Biomicrofluidics, 13(5), 051301(2019).
[35]. Escribá, R., Ferrer-Lorente, R. & Raya, Á. Inborn errors of metabolism: Lessons from iPSC models. Rev Endocr Metab Disord 22, 1189–1200 (2021).
[36]. Maoz, B. M. Brain-on-a-Chip: Characterizing the next generation of advanced in vitro platforms for modeling the central nervous system. APL Bioengineering, 5(3), 030902 (2021).
Cite this article
Wang,X. (2024). Advances in drug screening and toxicity testing: A review on Parkinson's disease using brain-on-a-chip. Theoretical and Natural Science,58,155-161.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 4th International Conference on Biological Engineering and Medical Science
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).